Marco Ruella, MD

Chen GM, Jain A, Gering DT, Satulovsky J, Datta S, Lai P, Karar J, Gonzalez VE, Alexander K, Chew A, Jadlowsky JK, Ruella M, Paruzzo L, Amses KR, Rech AJ, Stadtmauer EA, Frey NV, Hexner EO, Porter DL, Cohen AD, Gill SI, Garfall AL, Schuster SJ, Mo KC, Liang SI, Spasic M, Levine BL, Siegel DL, Ramírez-Fernández A, Cabanski CR, Yang E, Mackall CL, Bushman FD, Good Z, John Wherry E, June CH, Fraietta JA. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. , Nat Biomed Eng: 2026

Liu S, Guruprasad P, Ramasubramanian R, Madhu B, Paruzzo L, Han K, Kelly A, Shestov A, Xu HN, Carturan A, Zhou C, Amses KR, Afriat A, Litichevskiy L, Lin J, Dubowitz E, Tangal N, Zhang J, McSween A, Tan M, Stella F, Lee A, Nason S, Hua X, Schneider M, Sleeman M, Zhang Y, Gabrielli G, Yang Z, Pajarillo R, Patel R, Ghilardi G, Patel V, Joshi A, Jiang S, Jiang Y, Porazzi P, Tchou JC, Keith B, Li M, Chong E, Schuster SJ, Milone M, Rabinowitz J, O'Connor RS, Thaiss CA, Levy M, Ruella M. β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. , Cell, 189(6): 2026,1701-1716

Cohen IJ, Bochi-Layec AC, Lemoine J, Jenks S, Bayat P, Kim KH, Zhao H, Ugwuanyi O, Stella F, Ghilardi G, Gabrielli G, McCuaig S, Iatrou A, Vlachonikola E, Karipidou M, Bouziani E, Espie D, Ramasubramanian R, Agathangelidis A, Bhosale A, Paruzzo L, Medico G, Kolar B, Bugrovsky R, Guruprasad P, Wang LP, Harris J, Arons E, Zhang Y, Pajarillo R, Kreiger PA, Day CP, Sahinalp SC, Wu CH, Santi A, Fulmer B, Cases M, Palmer MB, Porazzi P, Wherry EJ, Kreitman RJ, Tiacci E, Apostolidis SA, Behrens EM, Bhoj V, Sanz I, Inghirami G, Schuster SJ, Ghia P, Stamatopoulos K, Ruella M. Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. , Sci Transl Med, 4(18): 2026,835

Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA. CD4(+) T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. , Nat Med., 32(2): 2026,702-716

Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee AE, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang AG, Barsouk A, Cho JH, Shaw CE, Singh EB, Ugwuanyi O, Paruzzo L, Stella F MD, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey AD Jr, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M. Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies. , Blood.: 2026

Ang Z, Castro A, Paruzzo L, Schimdt C, Hasanali ZS, Hayer KE, Stella F, Soldan SS, Torres-Diz M, Kwok C, Sainos PK, Ji K, Krohl PJ, Fine J, Sehgal P, Martinez D, Spangler JB, Riley JL, Vogl DT, Porazzi P, Pillai V, Lieberman PM, Allman D, Ruella M, Thomas-Tikhonenko A. The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target. , bioRxiv: 2026

Maillie L, Barta S, Carter J, Cook M, Hughes M, Landsburg D, Nasta SD, Ruella M, Schuster S, Svoboda J, Thomas C, Tomasulo E, Chong E. Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025

Paruzzo L, Ho M, Han Noll J, Stella F, Cohen I, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Huff A, Jarocha D, Koucky O, Hopkins C, Dimitri A, Lavorando M, Vogl D, Scholler J, Doto A, Everett J, Bushman F, Nathanson K, Porazzi P, Stadtmauer E, Susanibar-Adaniya S, Garfall A, Cohen A, Fraietta J, Ruella M. CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CARTmediated immune toxicities. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025

Lemoine J, Ghilardi G, Lee Y, Paruzzo L, Morena F, Perriello V, Li Z, Cohen I, Ugwuanyi O, Pajarillo R, Zhang Y, Guruprasad P, Patel R, Chong E, Nasta SD, Barta S, Garfall A, Landsburg D, Svoboda J, Sadigh S, Wasik M, Bhattacharyya, Porazzi P, Schsuter S, Falini B, Ruella M. Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025

Liu S, Guruprasad P, Ramasubramanian R, Madhu B, Paruzzo L, Han K, Shestov A, Zhou C, Lin J, Carturan A, Porazzi P, Chong E, Schuster S, Milone M, Thaiss C, Levy M, Ruella M. β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming. , In Proceedings of 67th American Society of Hematology Annual Meeting 2025: 2025